For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll

The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result